A multicentre, prospective, open-label study with [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2-antibody drug conjugates in patients with metastatic breast cancer (HER2-Ex PET) - HER2-Ex PET
Latest Information Update: 25 Nov 2025
At a glance
- Drugs Tezatabep matraxetan (Primary) ; Trastuzumab-deruxtecan
- Indications Advanced breast cancer
- Focus Therapeutic Use
Most Recent Events
- 17 Sep 2025 New trial record